Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!

About | View Sample | Privacy

Hottest Products

Compare Top Solutions in:

Evaluate more than 400,000 products >>

Featured Jobs

Laboratory Facility Manager
International AIDS Vaccine Initiative - New York, NY
Scientist/Sr. Scientist, Bio-analytical Chemistry
Dicerna Pharmaceuticals, Inc. - Watertown, MA
Hematology Oncology Consultant, Hematology - Louisiana North Job
Celgene Corporation - Louisiana, LA, US
Director, IT Global Operation Services, End-User Informatics Job
Celgene Corporation - Summit, NJ, US
Principal Scientist
Watson Pharmaceuticals - Fort Lauderdale, FL

More Jobs >>

Events

Pharmacovigilance and Risk Management Strategies 2012
January 22-25, 2012 — Arlington, Virginia
Just Released: New Trends in Preventive and Therapeutic Vaccine
Enforcement, Litigation and Compliance Conference
Dec. 6-7 — Washington, DC
New Paradigms to Fund & Move Biotech
January 11-12, 2012 — San Francisco, CA

More Events >>

Related Tags >> cholesterol

atherosclerosis News

Most Popular atherosclerosis Story

Experimental vax targets a key atherosclerosis trigger

June 9, 2010 — 2:15pm ET | By John Carroll

Researchers at the prestigious Karolinska Institute in Sweden are working on a new vaccine that could prevent the body from dispatching T cells to help ward off "bad" LDL cholesterol, inadvertently Read more...

atherosclerosis Press Releases

Spherix Regains Compliance With NASDAQ Listing Rule
PROLOR Biotech to Present at ILSI-Biomed 2011 Conference
PROLOR Biotech to Host Investor Conference Call
Cerenis Initiates Phase 2 Study of Lead Product Candidate, CER-001, in Patients with Acute Coronary Syndrome
Spherix Phase 2 Trial with D-tagatose Determines Minimum Dose for HbA1c and Triglycerides

Latest Headlines

Experimental vax targets a key atherosclerosis trigger
June 9, 2010

Paid Research Reports

Trends in mHealth and Telemedicine
The Global Aesthetic Dermatology Market Outlook
Future Directions in Regenerative Medicine
Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

More Research Reports >>

THE FIERCEMARKETS NETWORK